Business Context and Reporting Period
Immuneering Corporation filed a Form 8-K dated July 20, 2022, under Item 5.02 to report a planned change in its finance leadership. The filing identifies Immuneering as a biotechnology company headquartered in Cambridge, Massachusetts, with Class A common stock trading on Nasdaq under IMRX.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating and financial metrics.
Material Changes
- Biren Amin notified the company that he would step down as Chief Financial Officer, principal financial officer, principal accounting officer, and Treasurer to pursue another professional opportunity.
- Mr. Amin was expected to remain in those positions through August 10, 2022. The filing states that his departure was not due to any disagreement with the company regarding its operations, policies, or practices.
- The Board appointed Mallory Morales, then the company’s Vice President, Finance, as principal financial officer, principal accounting officer, and Treasurer, effective when Mr. Amin ceased serving in those roles.
Compensation, Outlook, and Risks
- Under a July 25, 2022 letter agreement, Ms. Morales will receive $30,000 in cash in two equal installments on August 15 and November 15, 2022, subject to continued service through each payment date.
- Subject to Board approval, Ms. Morales will receive an option to purchase 10,000 shares of Class A common stock and will enter into the company’s standard officer indemnification agreement.
- Ms. Morales has served as Vice President, Finance since May 2021 and previously held finance and accounting roles at Gilead Sciences, Immunomedics, and L’Oréal. She is a CPA.
- The filing provides no updated business guidance, financial outlook, contingencies, or unusual operating items.
Investor Verification Items
- Verify the effective transition date and whether Mr. Amin’s departure occurred as planned on August 10, 2022.
- Review Exhibit 10.1 for the complete terms of Ms. Morales’s compensation and equity award, including Board approval and vesting provisions.
- Assess subsequent filings for any additional finance leadership changes, financial results, liquidity updates, or disclosures regarding the transition.
- Note that the filing is dated July 20, while the disclosed appointment and letter agreement occurred on July 24 and July 25; investors should confirm the applicable event and filing chronology.